Ensuring equity in the era of HLA-restricted cancer therapeutics
In January 2022, the US Food and Drug Administration granted regulatory approval to tebentafusp, a bispecific T cell receptor protein that targets melanoma antigen gp100 in the context of the human leucocyte antigen (HLA) A*0201 allele. This approval generated significant excitement, given the relat...
Main Authors: | Michael Postow, James W Smithy, Amanda Blouin, Lisa C Diamond |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/11/e005600.full |
Similar Items
-
Ensuring equity with pre-clinical planning for chlamydia vaccines
by: Amanda L. Collar, et al.
Published: (2023-09-01) -
Transformation of the fuel and energy complex to ensure Russia’s energy security in the era of sanctions restrictions
by: V. Ya. Afanasiev, et al.
Published: (2023-11-01) -
HLA restriction of human cytotoxic T cells.
by: Mcmichael, A
Published: (1980) -
Ensuring equity: Pharmacogenetic implementation in rural and tribal communities
by: Tianna M. Leitch, et al.
Published: (2022-09-01) -
STRATEGIC PRIORITIES FOR ENSURING THE RETURN ON EQUITY OF UKRAINIAN ENTERPRISES
by: O. H. Chyrva, et al.
Published: (2017-12-01)